207 related articles for article (PubMed ID: 31395738)
1. iASPP mediates p53 selectivity through a modular mechanism fine-tuning DNA recognition.
Chen S; Wu J; Zhong S; Li Y; Zhang P; Ma J; Ren J; Tan Y; Wang Y; Au KF; Siebold C; Bond GL; Chen Z; Lu M; Jones EY; Lu X
Proc Natl Acad Sci U S A; 2019 Aug; 116(35):17470-17479. PubMed ID: 31395738
[TBL] [Abstract][Full Text] [Related]
2. Flexible Tethering of ASPP Proteins Facilitates PP-1c Catalysis.
Zhou Y; Millott R; Kim HJ; Peng S; Edwards RA; Skene-Arnold T; Hammel M; Lees-Miller SP; Tainer JA; Holmes CFB; Glover JNM
Structure; 2019 Oct; 27(10):1485-1496.e4. PubMed ID: 31402222
[TBL] [Abstract][Full Text] [Related]
3. Structure of High-Risk Papillomavirus 31 E6 Oncogenic Protein and Characterization of E6/E6AP/p53 Complex Formation.
Conrady MC; Suarez I; Gogl G; Frecot DI; Bonhoure A; Kostmann C; Cousido-Siah A; Mitschler A; Lim J; Masson M; Iftner T; Stubenrauch F; Travé G; Simon C
J Virol; 2020 Dec; 95(2):. PubMed ID: 33115863
[TBL] [Abstract][Full Text] [Related]
4. Structure of the E6/E6AP/p53 complex required for HPV-mediated degradation of p53.
Martinez-Zapien D; Ruiz FX; Poirson J; Mitschler A; Ramirez J; Forster A; Cousido-Siah A; Masson M; Vande Pol S; Podjarny A; Travé G; Zanier K
Nature; 2016 Jan; 529(7587):541-5. PubMed ID: 26789255
[TBL] [Abstract][Full Text] [Related]
5. Insight into the structural basis of pro- and antiapoptotic p53 modulation by ASPP proteins.
Ahn J; Byeon IL; Byeon CH; Gronenborn AM
J Biol Chem; 2009 May; 284(20):13812-13822. PubMed ID: 19246451
[TBL] [Abstract][Full Text] [Related]
6. Biochemical and structural studies of ASPP proteins reveal differential binding to p53, p63, and p73.
Robinson RA; Lu X; Jones EY; Siebold C
Structure; 2008 Feb; 16(2):259-68. PubMed ID: 18275817
[TBL] [Abstract][Full Text] [Related]
7. Sertad1 antagonizes iASPP function by hindering its entrance into nuclei to interact with P53 in leukemic cells.
Qiu S; Liu S; Yu T; Yu J; Wang M; Rao Q; Xing H; Tang K; Mi Y; Wang J
BMC Cancer; 2017 Nov; 17(1):795. PubMed ID: 29179704
[TBL] [Abstract][Full Text] [Related]
8. A previously identified apoptosis inhibitor iASPP confers resistance to chemotherapeutic drugs by suppressing senescence in cancer cells.
Li H; Zhang W; Zhao K; Zhao D; Zheng S; Hu Y
J Biol Chem; 2020 Mar; 295(12):4049-4063. PubMed ID: 32005663
[TBL] [Abstract][Full Text] [Related]
9. Suppression of iASPP-dependent aggressiveness in cervical cancer through reversal of methylation silencing of microRNA-124.
Dong P; Xiong Y; Watari H; Hanley SJ; Konno Y; Ihira K; Suzuki F; Yamada T; Kudo M; Yue J; Sakuragi N
Sci Rep; 2016 Oct; 6():35480. PubMed ID: 27765948
[TBL] [Abstract][Full Text] [Related]
10. miR-129 targets CDK1 and iASPP to modulate Burkitt lymphoma cell proliferation in a TAp63-dependent manner.
Zou H; Zou R; Chen K; Zhu C; Tian X; You Y; He X
J Cell Biochem; 2018 Nov; 119(11):9217-9228. PubMed ID: 30105797
[TBL] [Abstract][Full Text] [Related]
11. iASPP inhibits p53-independent apoptosis by inhibiting transcriptional activity of p63/p73 on promoters of proapoptotic genes.
Cai Y; Qiu S; Gao X; Gu SZ; Liu ZJ
Apoptosis; 2012 Aug; 17(8):777-83. PubMed ID: 22538442
[TBL] [Abstract][Full Text] [Related]
12. 2-anilino-4-amino-5-aroylthiazole-type compound AS7128 inhibits lung cancer growth through decreased iASPP and p53 interaction.
Cheng HW; Chein RJ; Cheng TJ; Wu PS; Wu HY; Hung PF; Wang CJ; Hsu YL; Wong JM; Yuan A; Wong CH; Yang PC; Pan SH
Cancer Sci; 2018 Mar; 109(3):832-842. PubMed ID: 29285847
[TBL] [Abstract][Full Text] [Related]
13. Peptide interactions stabilize and restructure human papillomavirus type 16 E6 to interact with p53.
Ansari T; Brimer N; Vande Pol SB
J Virol; 2012 Oct; 86(20):11386-91. PubMed ID: 22896608
[TBL] [Abstract][Full Text] [Related]
14. Papillomavirus E6 PDZ interactions can be replaced by repression of p53 to promote episomal human papillomavirus genome maintenance.
Brimer N; Vande Pol SB
J Virol; 2014 Mar; 88(5):3027-30. PubMed ID: 24352452
[TBL] [Abstract][Full Text] [Related]
15. Targeting an Interaction Between Two Disordered Domains by Using a Designed Peptide.
Mayer G; Shpilt Z; Bressler S; Marcu O; Schueler-Furman O; Tshuva EY; Friedler A
Chemistry; 2020 Aug; 26(45):10240-10249. PubMed ID: 32181542
[TBL] [Abstract][Full Text] [Related]
16. Identification of a novel isoform of iASPP and its interaction with p53.
Zhang X; Diao S; Rao Q; Xing H; Liu H; Liao X; Wang M; Wang J
J Mol Biol; 2007 May; 368(4):1162-71. PubMed ID: 17391696
[TBL] [Abstract][Full Text] [Related]
17. HEDGEHOG/GLI-E2F1 axis modulates iASPP expression and function and regulates melanoma cell growth.
Pandolfi S; Montagnani V; Lapucci A; Stecca B
Cell Death Differ; 2015 Dec; 22(12):2006-19. PubMed ID: 26024388
[TBL] [Abstract][Full Text] [Related]
18. Targeting the Two Oncogenic Functional Sites of the HPV E6 Oncoprotein with a High-Affinity Bivalent Ligand.
Ramirez J; Poirson J; Foltz C; Chebaro Y; Schrapp M; Meyer A; Bonetta A; Forster A; Jacob Y; Masson M; Deryckère F; Travé G
Angew Chem Int Ed Engl; 2015 Jun; 54(27):7958-62. PubMed ID: 26014966
[TBL] [Abstract][Full Text] [Related]
19. Degradation of p53 can be targeted by HPV E6 sequences distinct from those required for p53 binding and trans-activation.
Crook T; Tidy JA; Vousden KH
Cell; 1991 Nov; 67(3):547-56. PubMed ID: 1657399
[TBL] [Abstract][Full Text] [Related]
20. iASPP is over-expressed in human non-small cell lung cancer and regulates the proliferation of lung cancer cells through a p53 associated pathway.
Chen J; Xie F; Zhang L; Jiang WG
BMC Cancer; 2010 Dec; 10():694. PubMed ID: 21192816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
